VA-DEQUE-SYSTEMS
1.3.2021 17:02:06 CET | Business Wire | Press release
Deque Systems, the trusted leader in digital accessibility, announced today the availability of axe™ DevTools Pro. Built upon the wildly popular free axe browser extension, axe DevTools Pro is a huge step forward for digital equality, enabling dev teams to address accessibility at the source, using groundbreaking human and machine learning technology.
Developers and novices alike can use axe DevTools Pro to run automated and Intelligent Guided Tests™ on their websites and applications, which directly address the core blockages preventing people with disabilities from enjoying all the web has to offer. Axe DevTools Pro can identify 76 to 84 percent of accessibility issues on a webpage, the industry’s broadest range of options for detecting and remediating accessibility problems.
Over 19,000 developers and other users provided input to refine axe DevTools Pro during the 16-month beta period. Many of these suggestions have already been implemented.
Axe DevTools Pro is available now at www.deque.com/axe/devtools . There is a 14-day free trial, with no credit card required. It is then available for $40 per month, or $409 per year.
“With little effort or expertise, developers can now make meaningful change by significantly improving the user experience of their apps. By making your app accessible to people with disabilities, you’re shipping cleaner code and mitigating risk. Axe DevTools Pro was built to expand the impact developers can make, without disrupting existing processes,” says Dylan Barrell, Chief Technology Officer of Deque Systems. “With superior automation and guided tests, even novices can now conduct robust accessibility testing and remediation.”
Utilizing Deque’s industry-standard open source axe accessibility rules engine and machine learning, axe DevTools Pro’s Intelligent Guided Tests are based on simple question-and-answer interactions that don’t require accessibility expertise. Axe DevTools Pro walks developers through inspections of their websites and applications, allowing scans of full or partial pages, then produces and saves full reports highlighting areas for optimization.
Other available axe DevTools plans are:
Axe DevTools Enterprise: All axe DevTools Pro features are also available to Deque axe DevTools Enterprise customers. Enterprise users also enjoy CI/CD integration, CLI, enterprise security and support, and native Android and iOS tools.
Axe DevTools Free: Users who do not upgrade to Pro or Enterprise for their added feature sets, can continue to run automated tests using the axe DevTools browser extension for free.
“Axe DevTools is designed to help developers fix issues at the core while they code, the most agile method to resolve accessibility blockers as well as avoid future legal troubles,” says Preety Kumar, CEO of Deque Systems. “This is critical to avoiding re-work and helping speed the DevOps lifecycle while ensuring websites are usable to the more than 1 billion people in the world living with some form of disability who may rely on assistive technologies to navigate the Internet.”
About Deque Systems
Deque (pronounced dee-cue) is a web accessibility software and services company, and our mission is Digital Equality. We believe everyone, regardless of their ability, should have equal access to the information, services, applications, and everything else on the web.
We work with enterprise-level businesses and organizations to ensure that their sites and mobile apps are accessible. Installed in over 250,000 browsers and with over 4,000 audit projects completed, Deque is the industry standard.
Axe and Intelligent Guided Testing are trademarks of Deque Systems, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
